SecBot SecBot
8-K ·Filed Jul 9, 2026

VERA

Vera Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001193125-26-299165
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The CRO transition is unlikely to affect Vera's regulatory strategy or near-term stock performance. Monitor for any changes in regulatory submission timelines or pipeline updates in subsequent filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$42.45
T+0 close · Jul 9, 2026 · via day close
Latest settled
−28.34%
T+60 · $30.42
Vs SPY
−29.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 9 $42.45entry
  2. T+1 · 4mo ago −1.06%α −1.49% · $42.00
  3. T+5 · 4mo ago −7.84%α −7.71% · $39.12
  4. T+20 · 3mo ago −24.57%α −26.81% · $32.02
  5. T+60 · 7w ago −28.34%α −29.97% · $30.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vera Therapeutics announced the transition of Chief Regulatory Officer William Turner to Special Advisor for Regulatory Affairs, effective August 3, 2026, with Nancy Bowman, M.D., Ph.D., succeeding him as CRO. This is a routine, orderly leadership change with a named successor, carrying no material operational or financial implications.

Key Facts

  • William Turner steps down as Chief Regulatory Officer, transitions to Special Advisor for Regulatory Affairs effective August 3, 2026.
  • Nancy Bowman, M.D., Ph.D., appointed as the new Chief Regulatory Officer, effective August 3, 2026.
  • Orderly succession with both outgoing and incoming roles clearly defined.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-299165
Document: 0001193125-26-299165-index-headers.html0001193125-26-299165
Document: 0001193125-26-299165-index.html0001193125-26-299165
Document: 0001193125-26-299165.txt0001193125-26-299165

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 9, 2026